Myeloma
<ѻý class="page-description">More in Myeloma
News, features, and commentary about cancer-related issues
News, features, and commentary about cancer-related issues
High overall response rate, even though many were ineligible for trial leading to drug's approval
News, features, and commentary about cancer-related issues
News, features, and commentary about cancer-related issues
Incidence almost identical to that with standard cancer treatment in randomized trials
Systematic review and meta-analysis finds CAR T-cell-specific toxicities only account for 11.5%
Better survival in one registry study, detriment with class I HLA mismatch in another
News, features, and commentary about cancer-related issues
News, features, and commentary about cancer-related issues
News, features, and commentary about cancer-related issues
Indicated for newly diagnosed patients who are eligible for stem cell transplant
A third of patients who had received multiple prior lines of therapy responded, small study shows
News, features, and commentary about cancer-related issues
